玻璃体腔注射Bevacizumab治疗特发性脉络膜新生血管病变

发布时间：2018-03-14 23:06

本文选题：特发性脉络膜新生血管/药物疗法　切入点：脉络膜新生血管化/药物疗法　出处：《青岛大学》2011年硕士论文　论文类型：学位论文

【摘要】：目的评估抗血管内皮生长因子单克隆抗体Bevacizumab (Avastin)玻璃体腔注射治疗特发性脉络膜新生血管病变(Idiopathic choroidal neovascularization, ICNV)的疗效和安全性。方法对40例接受玻璃体腔注射Bevacizumab (2.5mg)治疗的ICNV病人进行回顾分析,主要评价指标包括最佳矫正视力(Best-corrected visual acuity, BCVA)、黄斑中心凹厚度(Central foveal thickness, CFT)。对注射后1月症状无改善或病情反复者并经眼底荧光素血管造影(Fundus fluorescein angiography, FFA)和/或光学相干断层扫描(Optical coherence tomography, OCT)证实者进行眼内重复注射。结果所有40例(40只眼)患者均完成至少6个月的随访,其中男性19例,女性21例,平均年龄33±6.8岁。治疗前患者的基线平均对数BCVA为0.66±0.35,CFT为275.39±107.591μm,注药后1个月平均对数BCVA为0.30±0.29 (P=0.000),CFT为185.39±45.77um(P=0.000)；本组患者经平均9.2个月的随访,平均对数BCVA提高至0.31±0.38(P=0.000),CFT降至192.38±55.52um(P=0.000),均较基线水平有显著改善。终末随访时符合视力提高者为27只眼(67.5%),稳定者8只眼(20%)。本组患者共接受了52次玻璃体腔内注射,平均注射次数为1.30次/眼,有63.6%患者在再注射术后1月视力提高两行或两行以上结论玻璃体腔注射Bevacizumab能够快速有效地改善或稳定多数特发性脉络膜新生血管病变的病情,但术后定期随访以及根据病情变化进行再次注射是必要的。
[Abstract]:Objective to evaluate the efficacy and safety of intravitreal injection of anti vascular endothelial growth factor monoclonal antibody Bevacizumab Avastin in the treatment of idiopathic choroidal neovascularization. Methods 40 patients with ICNV treated by intravitreal injection of Bevacizumab (2.5 mg) were retrospectively analyzed. The main evaluation measures included best corrected visual acuity, BCVA, central foveal thickness of macular fovea thickness. for those with no improvement or recurrence of symptoms on January after injection and fundus fluorescein angiographic (FFAs) and / or optical coherence tomography (Oct) after fundus fluorescein angiography (FFA). Repeat intraocular injection was performed in patients confirmed by optical coherence tomography (Oct). Results all 40 patients (19 males and 21 females) were followed up for at least 6 months. Mean age was 33 卤6.8.The baseline logarithmic BCVA of patients before treatment was 0.66 卤0.35 BCVA was 275.39 卤107.591 渭 m, and the average logarithmic BCVA of one month after injection was 0.30 卤0.29 P0.000CFT was 185.39 卤45.77umP0.000.The patients were followed up for an average of 9.2 months. The average logarithmic BCVA was increased to 0.31 卤0.38 ~ 0.38 卤55.52ump ~ (0.000), which decreased to 192.38 卤55.52ump ~ (0.000), which was significantly improved compared with the baseline level. At the end of follow-up, there were 27 eyes with improved visual acuity and 8 eyes with stable intravitreous intravitreous injection. The average number of injections was 1. 30 times per eye. 63.6% patients improved their visual acuity by two or more lines on January after reinjection. Conclusion Intravitreal injection of Bevacizumab can quickly and effectively improve or stabilize the condition of most idiopathic choroidal neovasculopathy, but it is necessary to follow up regularly after operation and to re-inject according to the changes of the disease.
【学位授予单位】：青岛大学
【学位级别】：硕士
【学位授予年份】：2011
【分类号】：R773.4

【相似文献】